Zeiss Vision expands its lab capabilities

Article

Carl Zeiss Vision (CZV) and US Optical of East Syracuse, NY, have signed a partnership agreement to manufacture Zeiss Individual and other CZV custom lenses on-site using the proprietary Zeiss PreciseForm process.

Key Points

San Diego-Carl Zeiss Vision (CZV) and US Optical of East Syracuse, NY, have signed a partnership agreement to manufacture Zeiss Individual and other CZV custom lenses on-site using the proprietary Zeiss PreciseForm process.

"US Optical is one of the most innovative labs in the country and has been a leader in free-form manufacturing since its inception," said Fred Howard, president, Americas-Pacific, CZV. "They are already a great partner for premium ZEISS traditional progressives and AR. The lab is the natural choice to become our latest partner for personalized lenses, and we are very pleased to extend our relationship with them."

US Optical has begun the extensive certification procedure for the proprietary Zeiss PreciseForm manufacturing process. When certification is complete later this year, the company will manufacture the full line of CZV customized, free-form progressive lenses.

Also, CZV–Florida, formerly Tri-City Optical, has begun manufacturing Zeiss Individual and other customized lenses in its recently remodeled facility.

The lab underwent the qualification process to meet the standards of PreciseForm manufacturing, which included the installation of free-form generators, ZEISS coating equipment, and robotic finishing equipment.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.